Literature DB >> 11576263

The clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma.

M.F. Milosevic1, A.J. Dembo, G.M. Thomas.   

Abstract

The prevalence of malignant peritoneal cytology in patients with International Federation of Obstetrics and Gynecology (1971) stage I endometrial carcinoma and its predictive value for recurrence of disease following hysterectomy were analyzed by numerically pooling the crude results of independent studies. Malignant cytology occurred in 8.3, 12.1 and 15.9% of patients with grade 1, 2 and 3 histology, respectively, and in 7.6% and 17.2% of patients with superficial and deep myometrial invasion, respectively. Prevalence was heterogeneous in the groups with grade 1 histology, grade 2 histology and superficial invasion, and homogeneous in the groups with grade 3 histology and deep invasion. This, together with a technical false positive rate of approximately 5% in the diagnosis of malignant cytology, suggests that the pooled values of prevalence for the low grade and superficially invasive groups may be overestimated. Malignant cytology was strongly associated with disease recurrence (pooled odds ratio of 4.7 with a 95% confidence interval of 3.5-6.3). Qualitative review of the literature suggests that this is largely due to the association of malignant cytology with other adverse prognostic factors which dominate the clinical course of the disease. In the absence of other adverse prognostic factors, the true prevalence of malignant cytology is low. This limits the clinical utility of cytology as an independent predictor of either overall recurrence or site of recurrence. Routine adjuvant treatment of patients with malignant cytology is therefore not justified.

Entities:  

Year:  1992        PMID: 11576263     DOI: 10.1046/j.1525-1438.1992.02050225.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer.

Authors:  Gunjal Garg; Feng Gao; Jason D Wright; Andrea R Hagemann; David G Mutch; Matthew A Powell
Journal:  Gynecol Oncol       Date:  2012-09-29       Impact factor: 5.482

2.  Controversies in the management of endometrial carcinoma: an update.

Authors:  Mohamed K Mehasseb; John A Latimer
Journal:  Obstet Gynecol Int       Date:  2012-02-16

3.  Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer.

Authors:  Farinaz Seifi; Vinita Parkash; Mitchell Clark; Gulden Menderes; Christina Tierney; Dan-Arin Silasi; Masoud Azodi
Journal:  JSLS       Date:  2019 Apr-Jun       Impact factor: 2.172

4.  Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients.

Authors:  Alvaro Tejerizo-García; Jesús S Jiménez-López; José L Muñoz-González; Sara Bartolomé-Sotillos; Laura Marqueta-Marqués; Gregorio López-González; José F Pérez-Regadera Gómez
Journal:  Onco Targets Ther       Date:  2013-09-16       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.